Literature DB >> 12390973

TRAIL induces death of human oligodendrocytes isolated from adult brain.

Mariola Matysiak1, Anna Jurewicz, Dariusz Jaskolski, Krzysztof Selmaj.   

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to induce apoptosis in various tumour cell lines and, recently, also in normal cells. TRAIL interacts with four receptors: two signalling receptors (TRAIL-R1 and TRAIL-R2) and two decoy receptors (TRAIL-R3 and TRAIL-R4). We have shown that both signalling receptors are present on the surface of oligodendrocytes isolated from adult human brain (ahOL), whereas the decoy receptors are expressed at a low level on ahOL. TRAIL induces ahOL apoptosis--as characterized by Annexin V staining prior to propidium iodide cell uptake--under conditions of protein synthesis inhibition. However, pre-treatment of ahOL with interferon gamma (IFNgamma) evoked susceptibility to TRAIL-induced death, which did not require inhibition of protein synthesis. A blocking experiment with monoclonal antibodies directed against TRAIL-R1 and TRAIL-R2 revealed that TRAIL-R1 is mainly involved in TRAIL-induced apoptosis of ahOL. In contrast to ahOL, microglial cells were completely resistant to cell death induced by TRAIL. Microglial cells had high surface expression of the decoy receptor TRAIL-R3, suggesting that resistance of these glial cells to TRAIL-induced death depends on the presence of the protective effect of TRAIL-R3. Stimulation of microglia with TRAIL increased further expression of TRAIL-R3, but it had no effect on the expression of TRAIL receptors by ahOL. This result may implicate TRAIL as an effector-immune molecule in selective ahOL demise in inflammatory/demyelinating conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390973     DOI: 10.1093/brain/awf254

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  16 in total

1.  Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions.

Authors:  Barbara Cannella; Stefanie Gaupp; Kakuri M Omari; Cedric S Raine
Journal:  J Neuroimmunol       Date:  2007-07-05       Impact factor: 3.478

2.  Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Authors:  Marjaneh Razmara; Brendan Hilliard; Azadeh K Ziarani; Ramachandran Murali; Srikanth Yellayi; Mustafa Ghazanfar; Youhai H Chen; Mark L Tykocinski
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 3.  Oligodendrocyte-microglia cross-talk in the central nervous system.

Authors:  Laura Peferoen; Markus Kipp; Paul van der Valk; Johannes M van Noort; Sandra Amor
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

4.  TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells.

Authors:  A M Nelson; Z Cong; K L Gilliland; D M Thiboutot
Journal:  Br J Dermatol       Date:  2011-08-17       Impact factor: 9.302

Review 5.  The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage.

Authors:  Wolfgang Brück
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 6.  Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination.

Authors:  Jens Watzlawik; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2010-03       Impact factor: 4.618

Review 7.  The signaling and apoptotic effects of TNF-related apoptosis-inducing ligand in HIV-1 associated dementia.

Authors:  Y Huang; N Erdmann; J Zhao; J Zheng
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

8.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 9.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

Review 10.  Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Violeta Rus; Takahiro Ito; Sonia Vlaicu; Anil Singh; Horea Rus
Journal:  J Neuroimmunol       Date:  2009-07-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.